StemCell Therapy

Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone. Overall survival data were immature at this time, but a clear positive trend has been observed. Follow-up will continue to the next analysis.

The rest is here:
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer...

Press Release

Read more:
Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6

SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted by the GMP MED office of the Agenzia Italiana del Farmaco (AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament.

Here is the original post:
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent...

Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030  ABP Live

Go here to see the original:
Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live

Mom who homeschools her children reveals she lets her one-year-old play in and EAT mud - but insists it is goo  Daily Mail

Here is the original post:
Mom who homeschools her children reveals she lets her one-year-old play in and EAT mud - but insists it is goo - Daily Mail

The limits of nutritional supplements: they dont cure or prevent ailments, nor are they harmless  EL PAS USA

Original post:
The limits of nutritional supplements: they dont cure or prevent ailments, nor are they harmless - EL PAS USA

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET.

View original post here:
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET

More here:
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows:

Here is the original post:
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across Europe and the U.S.

Read the original here:
Bavarian Nordic to hold Capital Markets Days in February 2024

BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami.

Read more here:
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Bright Green has achieved several key milestones throughout the Quarter advancing progress against its strategic plan.

Originally posted here:
Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced a new publication in the Lancet Infectious Diseases. The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and safety of VV116 (mindeudesivir hydrobromide tablets, product code: VV116/JT001) in patients with mild-to-moderate COVID-19. This study demonstrated that VV116 significantly reduced the time to sustained clinical symptom resolution compared to placebo, with no observed safety concerns.

View original post here:
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.

Visit link:
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

Read the original here:
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.

Go here to read the rest:
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

Bagsværd, Denmark, 23 November 2023 – Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Read more:
Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

See the article here:
Sanofi: Information concerning the total number of voting rights and shares - October 2023

Tokyo, Japan and Cambridge, UK, 24 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has initiated discussions with GSK to regain full ownership of GSK4381406, a highly selective first-in-class, oral GPR35 agonist in development under a Global Collaboration and License Agreement with GSK as a potential new treatment for Inflammatory Bowel Diseases (IBD). GPR35 is an important orphan G protein-coupled receptor (“GPCR”) with an established genetic association to IBD, for which there remains significant unmet need for millions of sufferers worldwide.

More here:
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer

View original post here:
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award